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Abstract
Introduction Only a limited number of tumor markers for breast
cancer are currently available. Antibodies to tumor-associated
proteins may expand the number of available tumor markers for
breast cancer and may be used together in a serum profile to
enhance sensitivity and specificity.
Methods In the present study, we interrogated a breast cancer
cDNA T7 phage library for tumor-associated proteins using
biopan enrichment techniques with sera from normal individuals
and from breast cancer patients. The enrichment of tumor-
associated proteins after biopanning was tested using a plaque-
lift assay and immunochemical detection. The putative tumor-
associated phage clones were collected for PCR and
sequencing analysis. Unique and open reading frame phage-
expressed proteins were then used to develop phage protein
ELISAs to measure corresponding autoantibodies using 87
breast cancer patients and 87 normal serum samples. A logistic
regression model and leave-one-out validation were used to
evaluate predictive accuracies with a single marker as well as
with combined markers. Identities of those selected proteins
were revealed through the sequence BLAST program.
Results We harvested 100 putative tumor-associated phage
clones after biopan enrichment. Sequencing analysis revealed
that six phage proteins were inframe and unique. Antibodies to
these six phage-expressed proteins were measured by ELISAs,
and the results showed that three of the phage clones had
statistical significance in discriminating patients from normal
individuals. BLAST results of the three proteins showed great
matches to ASB-9, SERAC1, and RELT. Measurements of the
three predictive phage proteins were combined in a logistic
regression model that achieved 80% sensitivity and 100%
specificity in prediction of sample status, whereas leave-one-out
validation achieved 77.0% sensitivity and 82.8% specificity
among 87 patient samples and 87 control samples. Receiver
operating characteristic curve analysis and the leave-one-out
method both showed that combined measurements of the three
antibodies were more predictive of disease than any of the
single antibodies studied, underscoring the importance of
identifying multiple potential markers.
Conclusion Serum autoantibody profiling is a promising
approach for early detection and diagnosis of breast cancer.
Rather than one autoantibody, a panel of autoantibodies
appears preferable to achieve superior accuracy. Further
refinements will need to be made to further improve the
accuracy. Once refined, the assay must be applied to a
prospective patient population to demonstrate applicability.
Introduction
In women, breast cancer is the most common malignancy and
the second most common cause of cancer-related mortality
[1]. Further reduction in the mortality will require successful
ELISA = enzyme-linked immunosorbent assay; BSA = bovine serum albumin; ORF = open reading frame; PBS = phosphate-buffered saline; PCR = 
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strategies for early detection and screening of the disease. A
sensitive assay to identify biomarkers that can accurately
determine the onset of breast cancer – especially if the tech-
nique is of low risk to the patient, such as blood drawing – is
ideal for early cancer detection.
Much of the effort in the past has centered on the discovery
and characterization of single tumor-associated antigens as
cancer markers. Two clinically used breast cancer antigens,
CA 15-3 and CA 27.29, are elevated in less than 10% of early-
disease patients and in about 75% of advanced-disease
patients. Neither antigen is recommended for screening or
diagnosis of onset breast cancer [2]. On the basis of the
marked heterogeneity of most human cancers, it is doubtful
that a single gene, chromosome aberration, or protein will pro-
vide sufficient accuracy for early detection.
In contrast to the detection of serum antigens, the detection of
serum antibodies to tumor antigens may provide reliable serum
markers for cancer diagnosis and prognosis [3-6]. Changes in
the level of gene expression [3,7-9] and aberrant expression of
tissue-restricted gene products [10,11] are factors in the
development of a humoral immune response in cancer
patients. There are several advantages of using serum anti-
bodies as markers for tumor development. First, tumor-associ-
ated autoantibodies circulate in the blood much earlier than
serum antigens. Autoantibodies to p53 have been reported in
patients with early-stage ovarian or colorectal cancers
[12,13], and a panel of serum antibodies can detect nonsmall-
cell lung cancer 5 years prior to autoradiograph detection
[14]. Second, antibodies may be more abundant than anti-
gens, especially at low tumor burden. Thirty percent of patients
with ductal carcinoma in situ in which the proto-oncogene
HER-2/neu was overexpressed had serum antibodies specific
to this protein [7,15]. In this respect, serologic analysis of
recombinant cDNA expression libraries of tumors with autolo-
gous serum has identified some relevant tumor antigens:
MAGE [16], SSX2 [17], and NY-ESO-1 [18].
We previously reported the use of combined autoantibodies
as markers for early detection of nonsmall-cell lung cancer
[14,19,20]. We achieved over 90% sensitivity and specificity
in diagnosing stage I nonsmall-cell lung cancer using five anti-
body markers in serum samples. Can the previously described
technique be applied to breast cancer? If so, can the tech-
nique provide sufficient sensitivity and specificity to be clini-
cally useful?
In the present study, we used similar techniques on a breast
cancer T7 cDNA phage library to identify tumor-associated
proteins. We then measured autoantibody reactivities to iden-
tified phage-expressed proteins in breast cancer patient sera
and normal sera by immunochemistry and ELISA to evaluate
the sensitivity and specificity of single versus combined anti-
body measurements for predicting probability of disease. We
further present the identities of corresponding proteins and
their relevance to tumor biology.
Methods
Human subjects
After investigational review board approved and informed con-
sent was obtained, 87 serum samples were obtained from
individuals with histologically confirmed stage I to stage III
breast cancer patients (11 stage I patients, 28 stage II patients
and 48 stage III patients). Eighty-seven normal control serum
samples were obtained from age-matched and sex-matched
cohorts. All of the samples were collected from Hebei Univer-
sity Affiliated Hospital.
Phage-display and biopanning process
A T7 phage breast cancer cDNA library (Novagen, Madison,
WI, USA) was biopanned with sera from five pooled breast
cancer patients and five pooled normal healthy donors, to
screen potential autoantigens recognized by circulating anti-
bodies in patient sera as previously described [19]. Briefly, the
phage-displayed library was affinity-selected by incubation
with protein G-agarose beads (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) coated with antibodies from pooled
normal sera (250 μl pooled normal sera, diluted 1:20, at 4°C
overnight) to remove nontumor-specific proteins. Unbound
phages were separated from phages bound to antibodies in
normal plasma by centrifugation. The supernatant was then
biopanned against protein G-agarose beads coated with
pooled patient plasma (4°C overnight) and separated from
unbound phages by centrifugation. The bound/reactive
phages were eluted with 1% sodium dodecyl sulfate and cen-
trifugation. The phages were amplified in Escherichia coli
BLT5615 (Novagen) in the presence of 1 mM isopropyl-β-D-
thiogalactopyranoside and carbenicillin (50 μg/ml) until lysis.
Amplified phage-containing lysates were collected and sub-
jected to three additional sequential rounds of biopan enrich-
ment. Bacterial cells were lysed by phage growth and yielded
titers of 3 × 109 plaque-forming units/ml enriched phages.
Immunodetection of antigen-expressing phages
To confirm the selection of four rounds of the biopanning pro-
cedure, limiting dilutions of phages from biopan 4 were used
to infect bacteria and were grown on a LB-Agar plate covered
with 6% agarose (LB-Agar/agarose). Phage plaques were
lifted twice by placing two nitrocellulose disk membranes (Mil-
lipore, Billerica, MA, USA) onto plaque-formed LB-Agar/agar-
ose plates (4°C, 2 hours. The lifted membranes were washed
with 1 × Tris-buffered saline plus 0.1% Tween 20 and were
blocked with 5% dry milk in 1 × Tris-buffered saline/Tween 20
for 1 hour at room temperature.
One membrane was probed with five pooled breast cancer
patient sera, and the other membrane was probed with five
pooled normal sera (1:7,500). Both patient sera and normal
sera were the same as those used in the previous biopans. TheAvailable online http://breast-cancer-research.com/content/10/3/R40
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membranes were followed by anti-human horseradish peroxi-
dase-conjugated secondary antibody (1:10,000; Jackson
ImmunoResearch, West Grove, PA, USA). The images were
detected with electrogenerated chemiluminescence (TianGen
Biotech, Beijing, China).
These two identical membranes allow a direct comparison of
the immunoreactivity of individual phage clones with pooled
patient and normal sera used in the biopan. Colonies corre-
sponding to highly immunoreactive spots on the membrane
were harvested from the original LB-Agar/agarose plate and
amplified in E. coli as previously described.
Sequencing and identification of phage-displayed 
tumor-associated proteins
Phage clones were isolated as above and the cDNA inserts
were PCR-amplified using commercially available T7 phage
vector primer (Novagen). The sequences are: T7 up, 5'-
GGAGCTGTCGTATTCCAGTC-3';  and T7 down, 5'-AAC-
CCCTCAAGACCCGTTTA-3'. Sequences of unique clones
were checked for the open reading frame (ORF) status in the
T7 expression vector. Only the correct ORF-encoded proteins
were identified by comparison with known sequences in the
GenBank database using the BLAST search program [21].
Measurement of antibodies to phage-expressed 
proteins
ELISAs were developed for the identified inframe phage-
expressed proteins to evaluate their immunogenic reactivity
with different patient serum. Ninety-six-well microtiter ELISA
plates (Jet Biofil, Guangzhou, China) were separately coated
with the identified ORF tumor-associated proteins or empty
phages as a negative control (2.5 × 1010 phage/well in 1 ×
PBS/0.1% BSA at 4°C overnight, were blocked (PBS/1%
BSA 37°C × 1 hour) and were washed (PBS/Tween 20). Seri-
ally diluted (1:20 to 1:10,240) serum samples from individual
patients that were not used in the biopan were added to each
well (37°C × 1 hour), and the plates were washed and then
incubated with anti-human horseradish peroxidase secondary
antibody (37°C × 1 hour). Assays were developed with tetram-
ethyl benzidine/H2O2 substrate (Amresco, Solon, OH, USA)
and stopped with 2 M H2SO4, and were then read on a spec-
trophotometer at 450λ. Each individual serum was run in
triplicate.
In separate experiments, sera were assayed at a single dilution
(1:320), and absorbance was used as a measure of antibody
reactivity in each independent assay. Eighty-seven patient
serum samples and 87 normal serum samples were assayed
for antibodies to the phages expressing inframe proteins. The
data were analyzed both individually for each marker and in
possible combinations of markers.
Statistical analysis
Using a panel of inframe phage-expressed proteins, logistic
regression analysis was performed to predict the probability
that a sample was from a breast cancer patient using SAS sta-
tistical software (SAS, Cary, NC, USA). Data for all 174 sam-
ples (87 patient samples and 87 normal samples) elicited from
the above ELISA test were randomly chosen to build up clas-
sifiers that were able to distinguish patient samples from nor-
mal samples on the basis of an individual marker or a
combination of markers.
Receiver operating characteristic curves were generated to
compare the area under the curve and the predictive sensitivity
and specificity with different markers using JMP software
(SAS Cary, NC, USA). The classifiers were further examined
by leave-one-out cross-validation.
Results
Selection of tumor-associated phage-expressed 
proteins
Comparison between duplicate plaque-lift membranes of bio-
pan 4, which were incubated with pooled breast cancer
patient sera or normal sera used in the biopan, showed the
ability of the biopan process to select immunogenic phage-
expressed proteins. Immunoreactivity of multiple phage-
expressed clones exhibited high-affinity binding with antibod-
ies in patient sera. In contrast, these same clones had low-
affinity binding in the identical membrane incubated with nor-
mal serum. The background seen on the membrane incubated
with the normal sera was considered nonspecific reactivity
with phage proteins (Figure 1).
One-hundred putative tumor-associated clones (darker spots)
were selected for PCR and sequencing analysis. Among the
Figure 1
Identification of disease-specific phage clones after the biopanning  process Identification of disease-specific phage clones after the biopan-
ning process. Two nitrocellulose membrane disks were placed on and 
then lifted from the same phage grown plate of biopan 4. (a) One mem-
brane was probed with pooled normal sera and (b) the other was 
probed with pooled patient sera. After electrogenerated chemilumines-
cence detection, numerous immunoreactive clones showed more inten-
sified spots on the membrane incubated with patient sera than on the 
membrane incubated with normal sera. The circle and square indicate 
the same area on the two membranes.Breast Cancer Research    Vol 10 No 3    Zhong et al.
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100 clones, six were found unique and expressing inframe
proteins, and 16 phage clones were found redundant and 78
clones were incorrect ORF with the T7 phage vectors. DNA
sequences of these six inframe proteins were then BLAST
against the GenBank database and homologies were found to
the following proteins: KLF17, COL6A1, GRWD1, ASB-9,
SERAC and RELT. The complete names and known functions
of the proteins are presented in Table 1.
Antibody affinity for phage-expressed proteins
To confirm antibody affinity in individual serum samples for
specific proteins, serum was assayed in limiting dilution from
1:20 to 1:10,240 by ELISA constructed with phages ASB-9,
SERAC1 and RELT, and T7 empty phages as control. Absorb-
ance values for each of the three antibodies showed decreas-
ing absorbance over serial dilutions in sera of three patients,
indicating the antigen-antibody binding affinities. T7 empty
phage controls exhibited background signals to patient sera
(Figure 2).
Measurement of antibody activities to open reading 
frame phage-expressed proteins
To assess the diagnostic potential of single antibody versus
combined antibody measurements, the six inframe phage-
expressed proteins KLF17, COL6A1, GRWD1, ASB-9,
SERAC1, and RELT were developed in ELISAs to measure
corresponding antibodies in individual patient sera and normal
sera. Logistic regression was used to model the probability
that a serum sample was from a breast cancer patient.
First, each of the six markers was included in the model indi-
vidually. RELT was the most significant (P = 0.0001) with an
area under the curve equal to 0.727, and the optimal predic-
tive accuracy was achieved with 53% sensitivity and 100%
specificity; whereas KLF17, COL6A1 and GRWD1 showed
no statistical significance (P = 0.091, P = 0.074 and P =
0.066, respectively) (Table 2).
Next, different combinations among the six markers were
tested in the model to determine the most optimal predictive
values. The combination of ASB-9, SERAC1 and RELT was
found to be the best grouping that produced an area under the
curve equal to 0.861, and 80% sensitivity and 100% specifi-
city (Figure 3).
To further validate the results, leave-one-out cross-validation
was carried out with the same data used above, and both the
individual and combined sensitivity and specificity were
decreased (Table 3). The most predictive value of the three
combined markers after the validations was 77.0% sensitivity
and 82.8% specificity.
Correlation of disease stages and diagnostic accuracies
To evaluate the ability of our assay in detection of early-stage
breast cancer patients, we analyzed our data in association
with the stages of the disease. After leave-one-out validation,
the results showed 54.5% sensitivity on detection of stage I
breast cancer patients, 75.0% sensitivity on stage II patients,
and 83.3% sensitivity on stage III patients (Table 4). These
results demonstrated that our combined biomarkers have
greater sensitivity and specificity in predicting breast cancer
patients than the traditional biomarkers.
Discussion
Serum tumor markers have the potential of being incorporated
into diagnostic and therapeutic practice in breast cancer [22-
26]. Potential usages of the markers include early detection or
screening, differentiation of benign from malignant disease,
histological differentiation, and defining prognosis. These
goals have generated considerable interests in identifying pre-
dictive tumor markers over the past three decades [27,28].
Besides CA 15-3 and CA 27.29, other breast tumor biomark-
ers have been identified. The most extensively investigated cir-
culating biomarkers include MAGE family members, NY-ESO-
1, HER-2/neu, MUC1, mutant p53, c-myc, BRCA1, and
Table 1
Proteins identified by biopanning from a breast cancer cDNA T7 phage library
Protein Full name; functions Score (bits), Ea value (alignment)
KLF17 Kruppel-like factor 17; new member of the Sp/KLF family of transcription factors in breast and 
prostate cancer
553, 1e-121 (100%)
COL6A1 Collagen, type VI, alpha 1; breast cancer and prostate cancer prognosis 626, 1e-143 (100%)
GRWD1 glutamate-rich WD repeat containing 1; overexpression in lung cancer, gastric cancer, and 
melanoma
545, 1e-152 (100%)
ASB-9 Ankyrin repeat and SOCS box protein 9; overexpression in breast cancer and prostate cancer 608, 1e-171 (100%)
SERAC1 Serine active site containing 1; unknown function 460, 3e-127 (100%)
RELT Receptor expressed in lymphoid tissues; stimulating T-cell proliferation in the presence of CD3 
signaling
422, 1e-115 (100%)
aThe Expect value (E) is a parameter that describes the number of hits one can "expect" to see by chance when searching a database of a 
particular size.Available online http://breast-cancer-research.com/content/10/3/R40
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BRCA2. Depending on the stage and histology of disease, the
percentage of breast cancer patients who have elevated
serum protein levels of any one of the above markers is less
than 36%, and combination of these markers ranges from
20% to 73% [22]. As such, the clinical application of these
markers is limited when assayed independently, although
using combinations of markers has somewhat enhanced diag-
nostic value [22]. Similarly, an antibody response to a single
protein is not expected to be a universal marker [29-32].
In the present study, we interrogated a breast cancer cDNA
T7 phage library with antibodies in patient sera to identify aber-
Figure 2
ELISA of phage-expressed proteins with individual serum samples ELISA of phage-expressed proteins with individual serum samples. Antigen ELISAs were developed with ASB-9-expressing, SERAC1-express-
ing and RELT-expressing phages. The assays were performed with serially diluted (1:20 to 1:10,240) individual serum samples that were not used 
in the biopan, to confirm measurements were representative of an antigen-antibody affinity reaction. Representative curves from three patients are 
shown for each protein. Empty (no inserts) T7 phages were used to show the nonspecific reaction backgrounds.
Table 2
Logistic regression analysis
Protein Area under the curve Specificity (%) Sensitivity (%) P value
KLF17a 0.474 100 27.3 0.0912
COL6A1a 0.482 100 32.7 0.0743
GRWD1a 0.4903 100 35.1 0.0656
ASB-9 0.593 100 41.2 0.0112
SERAC1 0.642 100 47.1 0.0009
RELT 0.727 100 52.9 0.0001
Three combined 0.861 100 80 0.0001
Area under the receiver operating characteristic curve indicates the diagnostic accuracy of biomarkers; the highest area = 1. aThese phage-
expressed proteins showed no statistical significance in distinguishing patient samples from normal samples either individually or in combination.Breast Cancer Research    Vol 10 No 3    Zhong et al.
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rantly expressed tumor proteins in breast cancer. Six correct
ORF phage-expressed proteins were isolated and the
corresponding antibody activities were measured by ELISA.
The classifier using three combined phage markers has given
good predictive accuracy using receiver operating character-
istic curve analysis. Although this predictive accuracy was
decreased by the leave-one-out validation from 174 samples,
the value is still more sensitive and specific than any other
biomarkers current used clinically.
We realized that the low percentage (6%) of ORF proteins of
the T7 phage library we used in the present study had limited
the number of inframe proteins that could be used for increas-
ing the sensitivity and specificity. To conquer this problem, we
have two potential solutions. First, we can choose a T7 phage
library that was constructed using oligo-dT primer rather than
random primers. Second, we can preselect the library by intro-
ducing second antibiotic genes at the C terminus of the
expression vector [33].
Overall, our conclusion that multiple antibody measurements
improve predictive accuracy is supported by the statistical
analysis, although we still need to assay more serum samples
against additional proteins to improve the statistical power and
to validate this as a clinically reliable approach. Furthermore,
the six sequences we identified in this study correspond to
known proteins that cover a broad functional range, suggest-
ing additional importance of this methodology for tumor biol-
ogy and for expanding the number of potential targets for novel
drug therapies and immunotherapies [34-43].
For diagnostic purposes, using an individual ELISA to measure
more than a few antibodies would be cumbersome, and the
measurement of all antibodies described here is impractical.
Efficient alternatives to the ELISA could facilitate development
of a highly predictive blood test for breast cancer. Fluorescent
microarray technology, applied generally to gene discovery,
and applied to high-throughput screening tumor-associated
antigens, may be ideal for this purpose. Robotic microarray
spotters that can group a comprehensive panel of phage-
expressed proteins onto identical chips make it possible to
reproducibly assay multiple antibodies in individual serum
samples simultaneously. Double fluorescence used in protein
microarray technology can decrease the false negative rate,
and can facilitate normalization. Protein microarray technology
is a powerful tool for screening tumor-associated antigens
[20,38,39].
The tumor-associated antibodies we identified in breast sera
have been described in other malignancies [40-43]. Given that
several tumor-associated proteins we found in breast cancer
are known to be expressed by other cancers, breast cancer
Figure 3
Comparisons of the specificity and sensitivity of logistic regression  models Comparisons of the specificity and sensitivity of logistic regres-
sion models. Data from quantitative ELISAs for three antibodies were 
evaluated for ability to predict disease. Lower curve: predictive accu-
racy using the logistic regression model with RELT data alone from 87 
patients and from 87 normal persons as the explanatory variable. The 
area under the curve is 0.727 and the model is significant (P = 
0.0001). Upper curve: predictive accuracy with the combination of 
ASB-9, SERAC1, and RELT as explanatory variables, where P = 
0.0001 and the area under the curve is 0.861.
Table 3
Leave-one-out validationa
Protein Specificity (%) Sensitivity (%) Diagnostic accuracyb (%)
ASB-9 64.7 58.5 61.8
SERAC1 70.6 52.9 61.7
RELT 76.5 64.7 70.6
Three combined 82.8 77.0 79.9
aOne sample was removed from the statistical model containing a total of 174 samples and a classifier was generated to predict the status 
(normal or patient) of the removed sample using the rest of the samples. This procedure was repeated for all samples. bDiagnostic accuracy = 
(number of true positive + number of true negative)/total number of samples.Available online http://breast-cancer-research.com/content/10/3/R40
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specificity will have to be individually evaluated. Even assum-
ing that no single putative marker is identified as being 100%
specific for breast cancer, combined measurements of multi-
ple markers may enhance the specificity. Testing a full panel of
antibodies for breast cancer specificity will be an important
part of assay validation and will eventually define clinical
applicability.
Our data support the rationale for the development of an
autoantibody panel for early detection and diagnosis of dis-
ease, and makes the identification of multiple proteins and
their corresponding antibodies both logical and timely. In sum-
mary, the techniques used here to identify immunogenic
proteins and their corresponding antibodies in peripheral
blood might generate a panel or a profile of diverse markers
that have significant diagnostic, therapeutic and scientific
promise.
Conclusion
In the present study we identified three breast tumor-associ-
ated proteins – ASB-9, SERAC 1 and RELT – from a breast
cancer cDNA T7 phage library screening with antibodies in
breast cancer sera. Through testing with 87 breast cancer
patient serum samples and 87 control serum samples, the
combined measurement of these three markers showed high
sensitivity and high specificity for breast cancer detection. Our
data indicate that antibody profiling is a promising approach
that could achieve high diagnostic accuracy for breast cancer.
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